Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases

References

• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27. doi:10.1158/1055-9965.EPI-15-0578
   PubMed Web of Science ®Google Scholar
• Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166557. doi:10.1016/j.bbadis.2022.166557
   PubMed Web of Science ®Google Scholar
• Brigell RH, Cagney DN, Martin AM. Local control after brain-directed radiation in patients with cystic versus solid brain metastases. J Neuro-oncol. 2019;142:355–363. doi:10.1007/s11060-019-03106-1
   PubMed Web of Science ®Google Scholar
• Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Front Oncol. 2020;10:1074. doi:10.3389/fonc.2020.01074
   PubMed Web of Science ®Google Scholar
• Franzin A, Vimercati A, Picozzi P, et al. Stereotactic drainage and Gamma knife radiosurgery of cystic brain metastasis. J Neurosurg. 2008;109:259–267. doi:10.3171/JNS/2008/109/8/0259
   PubMed Web of Science ®Google Scholar
• Kim M, Cheok S, Chung LK, et al. Characteristics and treatments of large cystic brain metastasis: radiosurgery and stereotactic aspiration. Brain Tumor Res Treat. 2015;3:1–7. doi:10.14791/btrt.2015.3.1.1
   PubMedGoogle Scholar
• Hayashi H, Okamoto I, Tanizaki J, et al. Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement. J Clin Oncol. 2014;32:e122–124. doi:10.1200/JCO.2012.48.2141
   PubMed Web of Science ®Google Scholar
• Lohle PN, Wurzer HA, Seelen PJ, Kingma LM, Go KG. Analysis of fluid in cysts accompanying various primary and metastatic brain tumours: proteins, lactate and pH. Acta Neurochir. 1998;140:14–19. doi:10.1007/s007010050051
   PubMed Web of Science ®Google Scholar
• Gaebe K, Li AY, Park A, et al. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. Lancet Oncol. 2022;23:931–939. doi:10.1016/S1470-2045(22)00271-6
   PubMed Web of Science ®Google Scholar
• Liu X, Yu Q, Zhang Z, et al. Same-day stereotactic aspiration and Gamma Knife surgery for cystic intracranial tumors. J Neurosurg. 2012;117:45–48. doi:10.3171/2012.7.GKS121019
   PubMed Web of Science ®Google Scholar
• Flickinger JC. Radiotherapy and radiosurgical management of brain metastases. Curr Oncol Rep. 2001;3:484–489. doi:10.1007/s11912-001-0069-5
   PubMedGoogle Scholar
• Park WH, Jang IS, Kim CJ, Kwon DH. Gamma knife radiosurgery after stereotactic aspiration for large cystic brain metastases. J Korean Neurosurg Soc. 2009;46:360–364. doi:10.3340/jkns.2009.46.4.360
   PubMed Web of Science ®Google Scholar
• Sathiyapalan A, Febbraro M, Pond GR, Ellis PM. Chemo-immunotherapy in first line extensive stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis. Curr Oncol. 2022;29:9046–9065. doi:10.3390/curroncol29120709
   PubMed Web of Science ®Google Scholar
• Pacheco J, Bunn PA. Advancements in small-cell lung cancer: the changing landscape following IMpower-133. Clin Lung Cancer. 2019;20:148–160.e142. doi:10.1016/j.cllc.2018.12.019
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 2021;22:51–65. doi:10.1016/S1470-2045(20)30539-8
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat Rev. 2011;37:242–249. doi:10.1016/j.ctrv.2010.07.005
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Park K, Govindan R. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: checkMate 451. J clin oncol. 2021;39:1349–1359. doi:10.1200/JCO.20.02212
   PubMed Web of Science ®Google Scholar
• Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: checkMate 331(☆). Ann Oncol. 2021;32:631–641. doi:10.1016/j.annonc.2021.01.071
   PubMed Web of Science ®Google Scholar
• Pujol JL, Greillier L, Audigier-Valette C, et al. A randomized non-comparative Phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial. J Thorac Oncol. 2019;14:903–913. doi:10.1016/j.jtho.2019.01.008
   PubMed Web of Science ®Google Scholar
• Xu YB, Zhang Y, Song Z, Wang W, Shao L. Treatment and prognosis of solid and cystic brain metastases in patients with non-small-cell lung cancer. Cancer Manage Res. 2021;13:6309–6317. doi:10.2147/CMAR.S314060
   PubMed Web of Science ®Google Scholar
• Narayanan V, Honce MJ, Mehrotra S, Camidge DR. Cystic brain metastases occurring in anaplastic lymphoma kinase gene rearranged non-small-cell lung cancer patients receiving crizotinib. Clin Lung Cancer. 2016;17:85–90. doi:10.1016/j.cllc.2015.07.003
   PubMed Web of Science ®Google Scholar
• Ismailoglu O, Albayrak BS, Ciris M. Cerebral metastasis of small-cell lung carcinoma mimicking a supratentorial cystic astrocytoma. Am J Med Sci. 2011;342(520). doi:10.1097/MAJ.0b013e3182206650
   PubMedGoogle Scholar
• Sun B, Huang Z, Wu S, et al. Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer. Oncotarget. 2016;7:74006–74014. doi:10.18632/oncotarget.12176
   PubMedGoogle Scholar
• Ebinu JO, Lwu S, Monsalves E, et al. Gamma knife radiosurgery for the treatment of cystic cerebral metastases. Int J Radiat Oncol Biol Phys. 2013;85:667–671. doi:10.1016/j.ijrobp.2012.06.043
   PubMed Web of Science ®Google Scholar
• Noda R, Akabane A, Kawashima M. Fractionated Gamma Knife radiosurgery after cyst aspiration for large cystic brain metastases: case series and literature review. Neurosurg Rev. 2022;45:3457–3465. doi:10.1007/s10143-022-01835-y
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Qin Q, Zhu H. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a cost-effectiveness analysis. Front Immunol. 2022;13:1044678. doi:10.3389/fimmu.2022.1044678
   PubMed Web of Science ®Google Scholar
• Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328:1223–1232. doi:10.1001/jama.2022.16464
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li Y, Dong Y, et al. Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: a case report. Front Oncol. 2022;12:846597. doi:10.3389/fonc.2022.846597
   PubMed Web of Science ®Google Scholar
• Hu H, Wang K, Jia R, et al. Current Status in Rechallenge of Immunotherapy. Int J Biol Sci. 2023;19:2428–2442. doi:10.7150/ijbs.82776
   PubMed Web of Science ®Google Scholar
• Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer. J Immunother. 2021;44:41–48. doi:10.1097/CJI.0000000000000337
   PubMed Web of Science ®Google Scholar
• Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865–871. doi:10.1001/jamaoncol.2020.0726
   PubMed Web of Science ®Google Scholar
• Fujisaki T, Watanabe S, Ota T, et al. The prognostic significance of the continuous administration of anti-PD-1 antibody via continuation or rechallenge after the occurrence of immune-related adverse events. Front Oncol. 2021;11:704475. doi:10.3389/fonc.2021.704475
   PubMed Web of Science ®Google Scholar
• Katayama Y, Shimamoto T, Yamada T, et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J Clin Med. 2019;9:102. doi:10.3390/jcm9010102
   PubMed Web of Science ®Google Scholar